Industry News

Hemostemix Inc. today announces a non-brokered private placement of subordinated secured convertible debentures for gross proceeds of up to Cdn $500,000. The proceeds from the Debenture issuance will be used for the advancement of the Company's phase 2 clinical trial for its lead product, ACP-01, and general corporate purposes. Elmar Burchardt, the Company's President& CEO, commented, "This is a significant step forward in our funding plans for the..."/>
Hemostemix Announces Offering
Sarepta Therapeutics, Inc., a developer of innovative RNA-targeted therapeutics, today announced that it has priced an underwritten public offering of an aggregate of 5.02 million shares of its common stock at a price to the public of $59.75 per share. In addition, Sarepta has granted the underwriters a 30- day option to purchase up to an additional 753,138 shares of common stock on the same terms and conditions as the initial shares sold to the underwriters."/>
Sarepta Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock
Ascendis Pharma A/S, a clinical stage biopharmaceutical company that applies its innovative TransCon technology to address significant unmet medical needs, today announced that it will webcast its R&D Update presentation on September 30, 2016 in New York City. Presentations will begin at 8:30 a.m. ET with outside experts and Ascendis senior management scheduled to speak. If you would like to attend, please send an email to..."/>
Ascendis Pharma A/S Announces Webcast of R&D Update
Alere Inc. will move the headquarters of its eScreen Inc. subsidiary to 8140 Ward Parkway, assisted by incentives from the Missouri Department of Economic Development. The state offered $5.1 million through the Missouri Works program, contingent on the company's job creation."/>
BRIEF: Alere eScreen moving from Overland Park to KC and adding jobs [The Kansas City Star]
Cigna have been accusing each other of breaching the terms of their merger agreement, according to a legal filing by the Justice Department. The proposed $48 billion deal is in limbo after the Justice Department sued in July to block it due to antitrust concerns. Nearly $2 billion is at stake should the deal not go through due to antitrust concerns."/>
Anthem, Cigna Accuse Each Other Of Breaching Merger Agreement [The Hartford Courant]
DaVita Kidney Care, a division of DaVita Inc., a leading provider of kidney care services in the United States, today announced the release of its "Slow Cooker Recipes" cookbook, a collection of kidney-friendly recipes that allow those on a kidney diet to have a delicious meal waiting for them when they get home while reducing time spent in the kitchen. This cookbook utilizes healthy ingredients that minimize potassium, phosphorus and sodium while..."/>
DaVita Kidney Care Celebrates First Day of Autumn with Slow Cooker Cookbook
Glaukos Corporation, an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that an international study published in the..."/>
International Study Shows Favorable 3-Year Results of 2 Glaukos iStent® Trabecular Micro-Bypass Stents as Initial Treatment for Naïve Glaucoma
Lantheus Holdings, Inc., the parent company of Lantheus Medical Imaging, Inc., a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents, today announced that new data from a sub-analysis of its first Phase 3 study of flurpiridaz F 18 for..."/>
Lantheus to Present New Data at the ASNC Annual Scientific Session on the Novel PET Cardiac Imaging Agent Flurpiridaz F 18 in Patients with Suspected Heart Disease Undergoing Exercise Stress Testing
UniQure Announces Management and Board Changes
IIROC Trade Resumption - I
Cryoport, Inc., the world's leading cryogenic logistics company dedicated to the life sciences, today announced the integration of its proprietary logistics technology, the Cryoportal™, with Database Integrations, Inc.' s Integrated Cell Therapy Automated Network scheduling platform. The integration of these two platforms is designed to solve the challenges of manufacturing, distribution and global supply chain planning for the..."/>
Cryoport and Database Integrations Launch Integrated Solution to Manage Patient and Manufacturer Schedules at Every Stage of the Clinical Trial Logistics Process
Veeva Systems Inc., a leading provider of industry cloud solutions for life sciences, will host its financial analyst and investor day in New York City on Thursday, September 29, 2016. The event will begin at 12:00 p.m. ET, with presentations starting at 1:00 p.m. ET and concluding at approximately 5:00 p.m. ET. Veeva will broadcast the presentations live on the company’ s investor relations website, ir.veeva.com, where a link to the archived webcast will..."/>
Veeva to Host Financial Analyst and Investor Day on Sept. 29, 2016
Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, at the request of Investment Industry Regulatory Organization of Canada on behalf of the Toronto Stock Exchange, confirms that as of the date of this news release, they are not aware of any corporate developments that would cause the recent..."/>
Intellipharmaceutics Responds to Recent Trading Activity
Adamas Pharmaceuticals, Inc. today announced the appointment of Michael F. Bigham, Chairman and Chief Executive Officer of Paratek Pharmaceuticals, Inc., to its Board of Directors. Bigham has broad management experience with over 25 years of senior leadership in the biotechnology industry.. “We welcome Michael to our board and look forward to his contributions as we transition Adamas into an organization with multiple commercial opportunities,”..."/>
Adamas Appoints Michael F. Bigham to Board of Directors
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer, will present at the LEERINK Partners Rare Disease& Immuno-Oncology Roundtable on Thursday, September 29, 2016, at 11:00 AM Eastern Daylight Time.. The live webcast will be accessible..."/>
Five Prime Therapeutics to Present at the LEERINK Partners Rare Disease & Immuno-Oncology Roundtable
Prothena Corporation plc, a late-stage clinical biotechnology company focused on the discovery, development, and commercialization of novel protein immunotherapies, today announced that members of its management team will discuss the Phase 2 development strategy for PRX003, the antibody in development for the potential treatment of inflammatory diseases, including psoriasis, during a webcast on September 29.. Conference Call and Webcast..."/>
Prothena to Host Update on PRX003 Phase 2 Development Strategy
Anika Therapeutics, Inc.,, a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid technology, today announced four data presentations on HYALOFAST, a biodegradable HA-based scaffold, at the 13 th World Congress of the International Cartilage Repair..."/>
Anika Announces Data Presentations on HYALOFAST Hyaluronic Acid-Based Scaffold at 2016 World Congress of the International Cartilage Repair Society
NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system disorders, today reported human factors data from a usability study focused on the interactions between Parkinson’ s disease patients and the mini-pump device used to administer ND0612, the Company’ s continuous, subcutaneously delivered levodopa/carbidopa liquid formulation. The data were presented today at the 4 th World Parkinson Congress,..."/>
NeuroDerm’s ND0612 Mini-Pump Delivery System Successfully Used by Parkinson’s Disease Patients in Home Setting
Tactile Systems Technology, Inc., a medical technology company that develops and provides innovative medical devices for the treatment of chronic diseases at home, announced today that it has received 510 clearance from the U.S. Food and Drug Administration for the Flexitouch System in treating lymphedema of the head and neck, a common consequence of head and neck cancer.. “This is a major milestone for our company and a first for the lymphedema..."/>
Tactile Medical Receives FDA 510(k) Clearance for New Indication of At-Home Lymphedema Treatment
Manitex Capital Inc. is pleased to announce that it has subscribed for and purchased unsecured convertible debentures of Cold Water Fisheries Inc. for an aggregate principal amount of $700,000. The Debentures have a maturity date of March 31, 2019 and the Principal Amount outstanding under the Debentures is convertible into common shares of CWF at the option of Manitex at any time prior to the Maturity Date. The conversion price is..."/>
Manitex Capital Inc. acquires convertible debentures of Cold Water Fisheries Inc. and provides advisory services on going-public transaction
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that Dr. Shankar Lakshman, a board-certified plastic surgeon and AcelRx clinical investigator, will present a subgroup analysis from the SAP301 study at the annual meeting of the American Society of Plastic Surgeons."/>
Findings from AcelRx Pharmaceuticals' Phase 3 SAP301 Study of ARX-04 in Abdominoplasty Patients to be Presented at Plastic Surgery Meeting
Eleven Biotherapeutics, Inc. has acquired Canada-based protein therapeutic technology company Viventia Bio Inc, the company said. Under the agreement, Eleven purchased all of the outstanding capital stock of Viventia in exchange for the issuance of 4,013,431 newly issued shares of Eleven common stock. This represented approximately 19.9% of the voting power of Eleven as of immediately prior to the..."/>
Eleven Biotherapeutics Buys Protein Therapeutic Technology Firm Viventia Bio
Cigna and UnitedHealth-- announced they would be pulling out of the Texas marketplace."/>
As insurers pull out, Obamacare sign comes down in Fort Worth [Fort Worth Star-Telegram]

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology667 Articles
Consumer Discretionary610 Articles
Financials441 Articles
Industrials379 Articles
Health Care379 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.